Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BDX 
Becton Dickinson and Company (BDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/11/2025: BDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $201.49
1 Year Target Price $201.49
| 4 | Strong Buy |
| 2 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.26% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/11/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 52.06B USD | Price to earnings Ratio 33.21 | 1Y Target Price 201.49 |
Price to earnings Ratio 33.21 | 1Y Target Price 201.49 | ||
Volume (30-day avg) 17 | Beta 0.28 | 52 Weeks Range 161.47 - 248.00 | Updated Date 11/11/2025 |
52 Weeks Range 161.47 - 248.00 | Updated Date 11/11/2025 | ||
Dividends yield (FY) 2.34% | Basic EPS (TTM) 5.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When Before Market | Estimate 3.92 | Actual 3.96 |
Profitability
Profit Margin 7.68% | Operating Margin (TTM) 14.96% |
Management Effectiveness
Return on Assets (TTM) 3.52% | Return on Equity (TTM) 6.54% |
Valuation
Trailing PE 33.21 | Forward PE 12.15 | Enterprise Value 70647013469 | Price to Sales(TTM) 2.38 |
Enterprise Value 70647013469 | Price to Sales(TTM) 2.38 | ||
Enterprise Value to Revenue 3.3 | Enterprise Value to EBITDA 14.37 | Shares Outstanding 286627469 | Shares Floating 285978587 |
Shares Outstanding 286627469 | Shares Floating 285978587 | ||
Percent Insiders 0.57 | Percent Institutions 93.48 |
Upturn AI SWOT
Becton Dickinson and Company
Company Overview
History and Background
Becton Dickinson and Company (BD) was founded in 1897. Initially, it was a medical supply company. BD has grown through innovation and acquisitions, becoming a global leader in medical technology.
Core Business Areas
- BD Medical: Produces medical devices and products used in medication delivery, infection prevention, and surgery.
- BD Life Sciences: Offers products for sample collection, diagnostics, and biosciences. Includes products for diagnostic systems and preanalytical systems.
- BD Interventional: Products for surgery, peripheral intervention, urology and critical care
Leadership and Structure
Thomas Polen is the Chairman, CEO, and President. BD operates with a functional organizational structure across its business segments.
Top Products and Market Share
Key Offerings
- Alaris System: Infusion pumps for hospitals; market share is significant in hospital settings. Competitors include Baxter, ICU Medical, and Smiths Medical. Accounts for a notable portion of BD's revenue in BD Medical segment.
- Vacutainer: Blood collection tubes; it is considered a market leader. Key competitors include Greiner Bio-One and Sekisui Diagnostics. Dominates a significant market share.
- Canto Flow Cytometer: Cell analysis instrument that is a market leader. Competitors include Thermo Fisher Scientific and Danaher. Revenue is significant in BD Life Sciences segment.
Market Dynamics
Industry Overview
The medical technology industry is driven by innovation, aging populations, and increasing healthcare spending.
Positioning
BD is a leading player in the medical technology industry, with a strong reputation for innovation and quality.
Total Addressable Market (TAM)
TAM in medical supplies and technology is estimated to be over $500 billion. BD holds a strong position in various segments, addressing a significant portion of this TAM. They are positioned well to capture more as the market grows.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Global presence
- Extensive product portfolio
- Established distribution network
- History of Innovation
Weaknesses
- High debt levels (especially post-acquisition)
- Exposure to currency fluctuations
- Potential for product recalls
- Reliance on healthcare spending
Opportunities
- Emerging markets growth
- Expanding product lines through R&D and acquisitions
- Increased adoption of point-of-care diagnostics
- Partnerships with healthcare providers
Threats
- Increased competition
- Pricing pressures from healthcare providers
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- MMM
- DHR
- SYK
- BSX
Competitive Landscape
BD possesses advantages in key areas like blood collection and medication delivery, but faces competition across its broader product portfolio. Competitors like Danaher and 3M have diverse offerings with similar market reach and innovative products.
Major Acquisitions
Parata Systems
- Year: 2022
- Acquisition Price (USD millions): 1525
- Strategic Rationale: Strengthens medication management capabilities in the pharmacy automation sector.
Tractor Supply Company
- Year: 2017
- Acquisition Price (USD millions): 24000
- Strategic Rationale: Acquiring CareFusion expanded medication management and patient safety solutions.
Growth Trajectory and Initiatives
Historical Growth: BD has grown steadily through acquisitions and organic growth over the past decade.
Future Projections: Analysts project moderate revenue growth in the coming years, driven by new products and market expansion.
Recent Initiatives: Recent initiatives include strategic acquisitions and investments in research and development.
Summary
Becton Dickinson is a robust player in the medical technology landscape, benefiting from a strong brand, wide product range, and global reach. Its revenue is pretty stable year to year. However, BD's high debt, potentially influenced by its acquisition strategy, and external pressures from competition and regulatory changes presents risks. Future growth relies on continued innovation, capitalizing on emerging markets, and navigating industry shifts to boost profitability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Becton Dickinson and Company
Exchange NYSE | Headquaters Franklin Lakes, NJ, United States | ||
IPO Launch date 1987-01-01 | President, CEO & Chairman Mr. Thomas E. Polen Jr. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 70000 | Website https://www.bd.com |
Full time employees 70000 | Website https://www.bd.com | ||
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.